Ann: Appendix 4C & quarterly update, page-24

The cost for pathogen testing kits are going up. The pricing is the key. Lets say one clinic was to acquire a kit from the states and get it shipped and wait for it to arrive. The true cost on the balance sheet is cost+delivery and real impact for the clinic is cost+ delivery + time + expected revenue loss.

I don't buy the argument that gross margins are here to stay where they are. It can easily explode and future PE will expand. There's so much opportunity here.

So far there's only been two Australian companies approved for legal sale of Covid 19 test kits in Australia. One is private. Others are Chinese.

Massive opportunities out there.

I guess thick stock will keep going up in increments as they keep signing clients, just like any other medical device supplier.